We have assembled an experienced team of executives with track records of success. Our leadership team is well versed in development, commercial, operational, and corporate functions—each crucial for long-term growth and well-being of a successful pharmaceutical business.

Pavan Cheruvu, MD

Chief Executive Officer

Dr. Cheruvu has served as the Chief Executive Officer of Axovant Sciences, Inc. since February 2018. Prior to joining Axovant, Dr. Cheruvu held roles of increasing responsibility at Roivant and supporting Axovant since 2015 and was appointed to the Roivant executive leadership team in 2017. A board-certified physician, Dr. Cheruvu completed his residency in internal medicine at Johns Hopkins Hospital and continued his training in a clinical fellowship in cardiovascular medicine at the University of California, San Francisco. Prior to his medical training, Dr. Cheruvu was a management consultant at McKinsey & Company, where he focused on biopharmaceutical strategy.

He earned his B.S.E. in biomedical engineering, B.S.E. in electrical engineering, and A.B. in chemistry from Duke University summa cum laude, his M.Sc. in computer science from Oxford University where he was a Rhodes Scholar, and his M.D. from Harvard Medical School.

Mark Altmeyer

President of Axovant Sciences GmbH &
Chief Commercial Officer

Mr. Altmeyer is President and Chief Commercial Officer of Axovant Sciences GmbH and joined our company in March 2015. He has 30 years of experience leading successful drug commercialization efforts as a pharmaceutical executive, with a focus on therapies for central nervous system disorders. Previously, he served as Chief Executive Officer and President of Otsuka America Pharmaceutical, Inc., where he led 1,700 employees and grew total revenues from $2.6 billion to over $5 billion. He led the launch of Abilify®, the top-selling CNS drug in history and the number-one selling drug in the United States in 2013. Earlier in his career, Mr. Altmeyer held a number of executive leadership roles at Bristol-Myers Squibb, including Senior Vice President, Global Commercialization, and Senior Vice President, Neuroscience Business Unit.

Mr. Altmeyer received an M.B.A. from Harvard Business School and a B.A. in economics from Middlebury College.

Gregory M. Weinhoff, MD

Chief Financial Officer

Dr. Weinhoff has served as Chief Financial Officer of Axovant Sciences, Inc. since August 2015. He has more than 20 years of experience in healthcare finance and operations, including as a venture capital investor, operating executive, and board member with Audit Committee experience. Previously, he was a partner at CHL Medical Partners, where he focused on investments in start-up and early-stage companies across therapeutics, diagnostics, medical devices and healthcare services. He was the founding Chief Executive Officer of Amicus Therapeutics and subsequently was a member of the Audit Committee of the company’s board of directors. Earlier in his career, he was founding President of VaxInnate and President of Resolvyx. He also held positions in the healthcare groups at J.H. Whitney & Co. and Morgan Stanley & Co.

Dr. Weinhoff received an M.D. from Harvard Medical School, an M.B.A. from Harvard Business School (Baker Scholar), and an A.B. in economics from Harvard College.

Stephen F. Mohr

General Counsel

Mr. Mohr has served as General Counsel of Axovant Sciences, Inc. since June 2017. He has more than 25 years of experience in legal and compliance matters affecting the pharmaceutical industry. He served in a number of senior roles during a 12-year career at AstraZeneca, including U.S. General Counsel and Deputy General Counsel, North America, and Global Compliance Officer. Prior to that, he held roles of increasing responsibility during a 14-year career at Bristol-Myers Squibb, including Vice President and Senior Counsel, U.S. Medicines. Earlier in his career, he specialized in litigation matters at Weiss Dawid Fross Zelnick & Lehrman, PC (now Fross Zelnick Lehrman & Zissu) and Rivkin Leff Sherman & Radler (now Rivkin Radler LLP).

Mr. Mohr received a J.D. from the University of Virginia School of Law and a B.A. in music from Yale University.

Ilise Lombardo, MD

Senior Vice President, Clinical Research

Dr. Lombardo has served as Senior Vice President of Clinical Research at Axovant Sciences, Inc. since April 2015. She has 15 years of experience leading clinical development and medical affairs programs across multiple therapeutic areas including neurological and psychiatric disorders. She has successfully managed clinical development, regulatory authority approval, and post-marketing activities. Previously, she was Vice President, Clinical Development and Medical Affairs, at FORUM Pharmaceuticals. Earlier in her career, she led multitherapeutic groups and development teams at Pfizer. She is a trained psychiatrist and previously worked in academic research and clinical practice. Prior to entering the pharmaceutical industry, she was an Assistant Professor of Clinical Research at Columbia University College of Physicians and Surgeons and the New York State Psychiatric Institute.

Dr. Lombardo received an M.D. from Yale University, an M.Phil. from the University of Cambridge, and an A.B. in philosophy from Brown University. She completed a research fellowship in molecular biology at Yale University and the University of Cambridge, and completed her internship and residency in psychiatry as well as a four-year post-doctoral fellowship in molecular neuroimaging at Columbia University College of Physicians and Surgeons.

Shankar Ramaswamy, MD

Senior Vice President, Business Development

Dr. Ramaswamy is Senior Vice President of Business Development at Axovant Sciences, Inc. and joined the company in March 2015. One of the earliest employees of Axovant, he has served the company in multiple roles including, most recently, Vice President of Global Medical Affairs.

Dr. Ramaswamy received an M.D. from Brown University and an A.B. in economics from Harvard University.